Drug Profile
Artesunate - Frantz Viral Therapeutics
Alternative Names: Artemisinin; Artesunic acid; DihydroartemisininLatest Information Update: 27 Jan 2024
Price :
$50
*
At a glance
- Originator Georgetown University
- Developer Frantz Viral Therapeutics; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Class 3-ring heterocyclic compounds; Antimalarials; Artemisinins; Small molecules; Succinates
- Mechanism of Action Cell inhibitors; Free radical stimulants; Sarcoplasmic reticulum calcium-transporting ATPase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Anal intraepithelial neoplasia; Cervical intraepithelial neoplasia
- No development reported Vulvar intraepithelial neoplasia
Most Recent Events
- 15 Jan 2024 Frantz Viral Therapeutics plans a phase II trial for Anal High-grade Squamous Intraepithelial Lesion in USA (Rectal) (NCT06206564)
- 12 Jan 2024 Phase-II clinical trials in Anal intraepithelial neoplasia in USA (unspecified route) (NCT06206564)
- 28 Nov 2023 No recent reports of development identified for phase-I development in Vulvar-intraepithelial-neoplasia(In the elderly, In adults) in USA (Topical, Ointment)